Hemoglobin News and Research

RSS

Sickle cell disease can be treated with resveratrol extract, according to researchers

An extract in red grape skin may be a new treatment for sickle cell disease, Medical College of Georgia researchers say.

23 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

New diabetes algorithm released by AACE for the management of type 2 diabetes

A new, first-of-its-kind diabetes algorithm created to help achieve glycemic (blood sugar) control in type 2 patients was published online today in the September/October edition of Endocrine Practice.

22 Oct 2009

OrSense presents data on its NBM-200MP system for hemoglobin and blood oximetry measurements

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented today at the American Association of Anesthesiologists (ASA) annual meeting, in New Orleans. The results from a multi-center study indicate that NBM-200MP, a continuous, non-invasive monitoring system, measures levels of oxygen saturation and hemoglobin accurately and reliably in comparison to accepted methods.

20 Oct 2009

Uninsured American adults with diabetes or high cholesterol often go undiagnosed and undertreated: Study

new study shows uninsured American adults with chronic illnesses like diabetes or high cholesterol often go undiagnosed and undertreated, leading to an increased risk of costly, disabling and even lethal complications of their disease.

20 Oct 2009

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Protalix BioTherapeutics, Inc., announced today positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive patients diagnosed with Gaucher disease.

15 Oct 2009

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

Findings may reveal new treatments for people suffering from chronic hemoglobin levels

A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people.

12 Oct 2009

New cancer drugs boost drug spending

Cancer treatments are on track to become the biggest driver of specialty pharmacy spending as its contribution to overall drug spending hit five percent for the first time in the first half of 2009, according to Medco Health Solutions, Inc.

8 Oct 2009

AMAG Pharmaceuticals to present three abstracts at ASN Renal Week meeting

AMAG Pharmaceuticals, Inc. today announced that three abstracts have been accepted for presentation at the American Society of Nephrology (ASN) Renal Week meeting being held October 27-November 1, 2009 in San Diego, CA.

8 Oct 2009

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin.

3 Oct 2009

Personal approach to psychological well-being

At the World Congress on Psychosomatic Medicine in Torino, Italy, Carol Ryff, Professor of Psychology at the University of Wisconsin, has described how, more than simply feeling happy, it is the personal approach to psychological well-being that matters.

26 Sep 2009

Study reveals that AIR Inhaled Insulin is inferior to SC insulin

The commercial failure of Exubera- (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market. Does this signal defeat for efforts to deliver insulin via the lungs? The science and circumstances behind the Lilly-Alkermes decision to discontinue trials of the AIR- inhaled insulin product are explored in a special supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The supplement is available free online at www.liebertpub.com/dia

24 Sep 2009

Phase III clinical trial results of DAR-31 published

Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.

14 Sep 2009

Newly discovered molecular circuit helps maintain proper body metabolism

Researchers at the University of Pennsylvania School of Medicine have discovered a molecular circuit involving heme that helps maintain proper metabolism in the body, providing new insights into metabolic disorders such as obesity and diabetes.

14 Sep 2009

Affymax to complete Hematide Phase 3 clinical study by the end of 2009

Affymax, Inc. today announced that it has notified clinical trial sites to complete treatment of patients in the Phase 3 clinical program for the investigational drug, Hematide, by the end of 2009.

10 Sep 2009

Nutrisystem D program helps overweight type 2 diabetic people lose weight

Results from a clinical study conducted at the Temple University School of Medicine and published today in the journal Postgraduate Medicine(1), show that a pre-packaged, portion controlled meal plan helped overweight individuals with type 2 diabetes lose significantly more weight and reduce their A1C test scores (a 90-day measure of blood sugar control) by almost a full point greater than those following a standard hospital-based diabetes support and education program, according to the findings.

9 Sep 2009

U.S. Army awards AWR certification for the Masimo Radical-7 and Rad-57 Pulse CO-Oximeters

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced that its Radical-7 and Rad-57 Pulse CO-Oximeters have achieved Airworthiness Release (AWR) Certification from the United States Army.

4 Sep 2009

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Children's Hospital & Research Center Oakland has completed its system-wide conversions to Masimo Rainbow SET Pulse CO-Oximetry technology.

2 Sep 2009

Hemoglobin News and Research

Sickle cell disease can be treated with resveratrol extract, according to researchers

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

New diabetes algorithm released by AACE for the management of type 2 diabetes

OrSense presents data on its NBM-200MP system for hemoglobin and blood oximetry measurements

Uninsured American adults with diabetes or high cholesterol often go undiagnosed and undertreated: Study

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

Findings may reveal new treatments for people suffering from chronic hemoglobin levels

New cancer drugs boost drug spending

AMAG Pharmaceuticals to present three abstracts at ASN Renal Week meeting

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Personal approach to psychological well-being

Study reveals that AIR Inhaled Insulin is inferior to SC insulin

Phase III clinical trial results of DAR-31 published

Newly discovered molecular circuit helps maintain proper body metabolism

Affymax to complete Hematide Phase 3 clinical study by the end of 2009

Nutrisystem D program helps overweight type 2 diabetic people lose weight

U.S. Army awards AWR certification for the Masimo Radical-7 and Rad-57 Pulse CO-Oximeters

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News